Abivax SA
IPOAbivax | Official Website
Public · Paris, France · Founded 2013 · $1.6B raised
- Headquarters
- Paris
- Employees
- 51–200
- Founded
- 2013
- Business Model
- B2B
- Website
- abivax.com
- Total Funding
- $1.6B
- Last Round
- $747.5M Corporate RoundJan 2025
- Rounds
- 5
- Type
- Public
About
Clinical-stage biotechnology company developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune system.
Summary
Abivax SA is a Biotech company based in Paris, France, founded in 2013. It has raised $1.6B in total across 5 rounds, most recently a $747.5M Corporate Round round in Jan 2025. Investors include TCGX and Sofinnova Partners.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Jan 2025
Sign up to see all 7 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Biopharmaceutical services company
Specialty pharmaceutical company
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...